Please ensure Javascript is enabled for purposes of website accessibility

Why Paratek Pharmaceuticals Crushed the Market Today

By Eric Volkman - Jun 1, 2021 at 6:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company gets off to a roaring start in June with an important FDA nod.

What happened

Shares of Paratek Pharmaceuticals (PRTK 8.98%) flew nearly 20% higher on Tuesday, on an otherwise forgettable day for the stock market. There was little mystery why -- the company won another approval for its next-generation antibiotic Nuzyra.

So what

Paratek announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (NDA) for the oral-only formulation of Nuzyra to treat adults suffering from community-acquired bacterial pneumonia (CABP), a lung disease.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

Previously, the FDA had approved Nuzyra in 2018 as a once-per-day oral and intravenous treatment for CABP, in addition to acute bacterial skin skin and skin structure infections (ABSSI).

The regulator's new approval means that the drug can be far more easily administered, and therefore more quickly deployed to patients.

In its press release trumpeting the latest green light for its drug, Paratek quoted its chief commercial officer Adam Woodrow as saying "The approval of an oral-only dose regimen for Nuzyra in pneumonia represents a significant opportunity to offer clinicians the ability to treat patients in either the outpatient or primary care setting."

"Treating in this way potentially reduces or eliminates hospitalizations and the associated risk and costs from a hospital stay," Woodrow added.

Now what

It's almost always good news, both for the biotech that developed it and the patients that will be treated for its target affliction, when a much easier treatment regime of a drug is approved. Nuzyra should see a commensurate rise in sales following the FDA's latest nod.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Paratek Pharmaceuticals, Inc. Stock Quote
Paratek Pharmaceuticals, Inc.
PRTK
$2.79 (8.98%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.